ADAR1 Capital Buys InMed Shares: What It Means for Investors and the Growing Cannabinoid Market
ADAR1 Capital’s recent buy‑in of InMed Pharma signals confidence in its cannabinoid pipeline and regulatory prospects—could spark a micro‑cap rally for savvy investors.
4 minutes to read
